vs
艾伯维（ABBV）与RxSight, Inc.（RXST）财务数据对比。点击上方公司名可切换其他公司
艾伯维的季度营收约是RxSight, Inc.的509.6倍（$16.6B vs $32.6M）。艾伯维净利率更高（10.9% vs -28.1%，领先39.0%）。艾伯维同比增速更快（10.0% vs -18.9%）。艾伯维自由现金流更多（$4.9B vs $-2.3M）。过去两年艾伯维的营收复合增速更高（16.2% vs 5.1%）
艾伯维是一家总部位于美国伊利诺伊州北芝加哥的制药企业，专注于研发、生产覆盖多种疾病领域的治疗药物，致力于为全球各地患者提供安全有效的临床解决方案，在全球医药行业拥有较高的知名度与影响力。
RxSight是一家医疗科技企业，专注于研发和商业化适用于白内障及屈光晶状体置换手术的可调光人工晶状体产品，其核心产品支持术后通过专用照光设备调整晶状体度数，为全球眼科诊疗市场提供优化的术后视力解决方案。
ABBV vs RXST — 直观对比
营收规模更大
ABBV
是对方的509.6倍
$32.6M
营收增速更快
ABBV
高出29.0%
-18.9%
净利率更高
ABBV
高出39.0%
-28.1%
自由现金流更多
ABBV
多$4.9B
$-2.3M
两年增速更快
ABBV
近两年复合增速
5.1%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $16.6B | $32.6M |
| 净利润 | $1.8B | $-9.2M |
| 毛利率 | 72.6% | 77.5% |
| 营业利润率 | 27.3% | -34.8% |
| 净利率 | 10.9% | -28.1% |
| 营收同比 | 10.0% | -18.9% |
| 净利润同比 | 8354.5% | -54.1% |
| 每股收益（稀释后） | $1.02 | $-0.22 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ABBVRXST
| Q4 25 | $16.6B | $32.6M | ||
| Q3 25 | $15.8B | $30.3M | ||
| Q2 25 | $15.4B | $33.6M | ||
| Q1 25 | $13.3B | $37.9M | ||
| Q4 24 | $15.1B | $40.2M | ||
| Q3 24 | $14.5B | $35.3M | ||
| Q2 24 | $14.5B | $34.9M | ||
| Q1 24 | $12.3B | $29.5M |
净利润ABBVRXST
| Q4 25 | $1.8B | $-9.2M | ||
| Q3 25 | $186.0M | $-9.8M | ||
| Q2 25 | $938.0M | $-11.8M | ||
| Q1 25 | $1.3B | $-8.2M | ||
| Q4 24 | $-22.0M | $-5.9M | ||
| Q3 24 | $1.6B | $-6.3M | ||
| Q2 24 | $1.4B | $-6.1M | ||
| Q1 24 | $1.4B | $-9.1M |
毛利率ABBVRXST
| Q4 25 | 72.6% | 77.5% | ||
| Q3 25 | 66.4% | 79.9% | ||
| Q2 25 | 71.8% | 74.9% | ||
| Q1 25 | 70.0% | 74.8% | ||
| Q4 24 | 70.9% | 71.6% | ||
| Q3 24 | 70.9% | 71.4% | ||
| Q2 24 | 70.9% | 69.5% | ||
| Q1 24 | 66.7% | 70.1% |
营业利润率ABBVRXST
| Q4 25 | 27.3% | -34.8% | ||
| Q3 25 | 12.1% | -40.1% | ||
| Q2 25 | 31.7% | -41.6% | ||
| Q1 25 | 28.0% | -28.2% | ||
| Q4 24 | -9.9% | -21.5% | ||
| Q3 24 | 26.5% | -26.1% | ||
| Q2 24 | 27.6% | -23.9% | ||
| Q1 24 | 22.7% | -36.2% |
净利率ABBVRXST
| Q4 25 | 10.9% | -28.1% | ||
| Q3 25 | 1.2% | -32.4% | ||
| Q2 25 | 6.1% | -35.0% | ||
| Q1 25 | 9.6% | -21.6% | ||
| Q4 24 | -0.1% | -14.8% | ||
| Q3 24 | 10.8% | -17.9% | ||
| Q2 24 | 9.5% | -17.4% | ||
| Q1 24 | 11.1% | -30.8% |
每股收益（稀释后）ABBVRXST
| Q4 25 | $1.02 | $-0.22 | ||
| Q3 25 | $0.10 | $-0.24 | ||
| Q2 25 | $0.52 | $-0.29 | ||
| Q1 25 | $0.72 | $-0.20 | ||
| Q4 24 | $-0.03 | $-0.14 | ||
| Q3 24 | $0.88 | $-0.16 | ||
| Q2 24 | $0.77 | $-0.16 | ||
| Q1 24 | $0.77 | $-0.25 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $5.3B | $228.1M |
| 总债务越低越好 | $58.9B | — |
| 股东权益账面价值 | $-3.3B | $275.7M |
| 总资产 | $134.0B | $311.8M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ABBVRXST
| Q4 25 | $5.3B | $228.1M | ||
| Q3 25 | $5.7B | $227.5M | ||
| Q2 25 | $6.5B | $227.5M | ||
| Q1 25 | $5.2B | $229.3M | ||
| Q4 24 | $5.6B | $237.2M | ||
| Q3 24 | $7.3B | $237.1M | ||
| Q2 24 | $13.2B | $233.3M | ||
| Q1 24 | $18.1B | $125.4M |
总债务ABBVRXST
| Q4 25 | $58.9B | — | ||
| Q3 25 | $63.0B | — | ||
| Q2 25 | $63.0B | — | ||
| Q1 25 | $64.5B | — | ||
| Q4 24 | $60.3B | — | ||
| Q3 24 | $58.5B | — | ||
| Q2 24 | $58.0B | — | ||
| Q1 24 | $63.8B | — |
股东权益ABBVRXST
| Q4 25 | $-3.3B | $275.7M | ||
| Q3 25 | $-2.6B | $276.0M | ||
| Q2 25 | $-183.0M | $278.0M | ||
| Q1 25 | $1.4B | $279.3M | ||
| Q4 24 | $3.3B | $281.2M | ||
| Q3 24 | $6.0B | $277.3M | ||
| Q2 24 | $6.8B | $275.2M | ||
| Q1 24 | $8.0B | $163.9M |
总资产ABBVRXST
| Q4 25 | $134.0B | $311.8M | ||
| Q3 25 | $133.9B | $308.5M | ||
| Q2 25 | $137.2B | $309.0M | ||
| Q1 25 | $136.2B | $313.0M | ||
| Q4 24 | $135.2B | $318.6M | ||
| Q3 24 | $143.4B | $310.5M | ||
| Q2 24 | $141.9B | $305.5M | ||
| Q1 24 | $148.9B | $183.2M |
负债/权益比ABBVRXST
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 45.44× | — | ||
| Q4 24 | 18.15× | — | ||
| Q3 24 | 9.70× | — | ||
| Q2 24 | 8.56× | — | ||
| Q1 24 | 7.97× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $5.2B | $-1.1M |
| 自由现金流经营现金流 - 资本支出 | $4.9B | $-2.3M |
| 自由现金流率自由现金流/营收 | 29.4% | -6.9% |
| 资本支出强度资本支出/营收 | 2.0% | 3.5% |
| 现金转化率经营现金流/净利润 | 2.87× | — |
| 过去12个月自由现金流最近4个季度 | $17.8B | $-19.3M |
8季度趋势，按日历期对齐
经营现金流ABBVRXST
| Q4 25 | $5.2B | $-1.1M | ||
| Q3 25 | $7.0B | $-1.2M | ||
| Q2 25 | $5.2B | $-4.4M | ||
| Q1 25 | $1.6B | $-8.8M | ||
| Q4 24 | $7.0B | $-4.3M | ||
| Q3 24 | $5.4B | $650.0K | ||
| Q2 24 | $2.3B | $-4.0M | ||
| Q1 24 | $4.0B | $-9.3M |
自由现金流ABBVRXST
| Q4 25 | $4.9B | $-2.3M | ||
| Q3 25 | $6.6B | $-1.8M | ||
| Q2 25 | $4.9B | $-5.9M | ||
| Q1 25 | $1.4B | $-9.4M | ||
| Q4 24 | $6.8B | $-5.1M | ||
| Q3 24 | $5.2B | $-453.0K | ||
| Q2 24 | $2.0B | $-5.5M | ||
| Q1 24 | $3.8B | $-11.3M |
自由现金流率ABBVRXST
| Q4 25 | 29.4% | -6.9% | ||
| Q3 25 | 42.1% | -5.8% | ||
| Q2 25 | 31.7% | -17.6% | ||
| Q1 25 | 10.5% | -24.8% | ||
| Q4 24 | 44.7% | -12.7% | ||
| Q3 24 | 35.9% | -1.3% | ||
| Q2 24 | 14.0% | -15.9% | ||
| Q1 24 | 31.3% | -38.2% |
资本支出强度ABBVRXST
| Q4 25 | 2.0% | 3.5% | ||
| Q3 25 | 2.4% | 1.9% | ||
| Q2 25 | 1.7% | 4.6% | ||
| Q1 25 | 1.8% | 1.5% | ||
| Q4 24 | 1.9% | 2.1% | ||
| Q3 24 | 1.7% | 3.1% | ||
| Q2 24 | 1.7% | 4.4% | ||
| Q1 24 | 1.6% | 6.7% |
现金转化率ABBVRXST
| Q4 25 | 2.87× | — | ||
| Q3 25 | 37.76× | — | ||
| Q2 25 | 5.49× | — | ||
| Q1 25 | 1.27× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 3.49× | — | ||
| Q2 24 | 1.66× | — | ||
| Q1 24 | 2.95× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ABBV
暂无分部数据
RXST
| Rxlal | $28.2M | 86% |
| LDD | $3.0M | 9% |
| Service Warranty Service Contracts And Accessories | $1.5M | 4% |
